Could We See PsyBio Therapeutics Corp Become the Next Billion-Dollar Biotech Stock?
When Comparing Their Pharmaceutical Candidates to Other Billion-Dollar Biotechs in One of the Fastest Growing Sectors
Institutional Investors Are Pouring Money
Into This Sector
Find Out Why This Biotech Could Be at the Top of Their Lists
Retail investors are always last to know when an up-and-coming biotech industry is going to take off. It might be worth following the money trail in a sector that is getting a lot of attention from major institutional investors.
PsyBio Therapeutics is creating a portfolio of unique, scientifically developed, psychoactive compounds as potential therapeutic agents for mental and neurologic health issues.
- BREAKING NEWS -
Very Few In This Sector Have Accomplished What PsyBio Has Accomplished.
The Other Companies Are Trading At Billion or Multibillion-Dollar Valuations.
PsyBio sits right around $30 million.
1. PsyBio has compiled an ever-expanding portfolio of over 80 molecules, utilizing scientific methodology to prioritize ongoing development
2. PsyBio is an industry-first and leader in developing cheaper, faster, and greener
psychedelic inspired compound discovery and production
3. PsyBio has contracted with three globally acclaimed and experienced contract
manufacturing organizations for process development and commercialization of lead
4. PsyBio is one of a small number of companies actively working towards US FDA
sanctioned clinical trials in the psychedelic inspired biotherapeutic space
Beginner at OTC Stocks?
4400 West Sample Rd,
Coconut Creek, FL 33073
513 | 449 | 9585
PsyBio Therapeutics is developing biosynthetic psychoactive and other unique compounds which potentially offer a new paradigm of treatment to reverse the course of mental health issues and other disorders.
Psybio Therapeutics Corp.
(OTCQB: PSYBF) (TSXV: PSYB)
Market Cap: 30 Million
*Approximate market cap as of 10/12/21
Take A Look At Other Similar Companies And Where They Are Today
*Approximate market cap as of 10/12/21
Why PsyBio Will be the Leader in the
Psy-che-delic Drug Discovery Business
Psybio set out to raise $5 million in its go public round and was oversubscribed with over $17 million, finally accepting $14 million, half of it coming from dedicated life science institutional investors.
Psybio raised enough capital for two years of runway which includes submissions to the FDA in 2021.
PsyBio retains the global exclusive rights to a platform technology enabling highly efficient drug discovery, development, and production for pharmaceutical candidates through synthetic biology and metabolic engineering.
Psybio has a portfolio of over 80 molecules and growing by utilizing the genetics of hallucinogenic plants and fungi.
PsyBio has its own dedicated animal testing center and performs experiments on drug candidates on a daily basis.
Psybio is working with three globally acclaimed contract manufacturers for process development on its psilocybin compound and its derivatives.
Psybio's management team has submitted thousands of FDA applications for therapeutics, diagnostics and devices and managed thousands of clinical trials.
PsyBio World-Class Management Team
Management is key to a successful biotechnology company in obtaining FDA approval for its leading therapeutic candidates.
Experienced CEO with over 25 years in the Biotechnology Industry
Prior Successful Uplisting to Major Exchanges
Raised Hundreds of Millions from Institutional Investors for Life Sciences Companies
Overseen Phase 2 and 3 Clinical Trials on Multiple Continents
Chief Medical Officer with Extensive Clinical Trial and Regulatory .........Experience
Expertise with FDA, Health Canada, EMA, PMDA, CFDA Applications
Served as Protocol Designer, Lead Investigator, Regulatory Strategist, and Sponsor for Numerous Phase 1 through 4 Clinical Trials for Drug, Device and Diagnostic Products
Ability to secure FDA and Other Regulatory Body Approvals
Miami University, Oxford Ohio
Collaborative Research for Candidate Discovery and Animal Testing funded by Psybio
World-Class Board of Directors
Venture Capital-Backed Business Operators
Experienced in Finance, Mergers and Acquisitions and Integrations
Operational Vigilance & Efficiency
Expertise in Life Sciences, Medical Technology, and Consumer Healthcare
Mental Health Challenges Have a Large Socioeconomic Cost
New Studies are demonstrating that alternative treatments may treat mental health issues, like:
Obsessive-Compulsive Disorder (OCD)
Psybio is leading the industry in drug discovery and development setting out to prove new methods can’t be overlooked by Big Pharma anymore.”
Current Market Size for the Pharmacologic Treatment of Mental Illnesses is Large
PsyBio’s Progress in Development of Pharmaceutical Candidates Targeting the Treatment of Mental Health
Challenges and Neurological Disorders
1. Ongoing commercialization of an efficient, patent-pending bacterial biosynthesis process for the production of therapeutic candidates.
2. Developing a scientifically based portfolio of therapeutic candidates based initially on psychedelic agents.
3. Understanding the innate synergy between psychoactive compounds in a laboratory-controlled
Endeavoring to Improve Mental and
The current Standard of Care for the treatment of depression and anxiety involves the use of FDA-approved agents including SSRI’s, SNRI’s, MAOI’s, NDRI’s, and others. While these drugs have revolutionized the treatment of psychiatric disorders there remains a tremendous unmet need for those individuals with less than fully treated mental and neurological health conditions. Utilizing a proprietary platform technology to
biologically synthesize selected, targeted next-generation active compounds, PsyBio is able to fully test compounds for their activity and safety moving the successful candidates into clinical practice.
This website/media webpage is owned, operated, and edited by 154 Agency LLC. Any wording found on this website/media webpage or disclaimer referencing to “I” or “we” or “our” or “154 Agency” refers to 154 Agency LLC. This website/media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website/media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature. Therefore, we are unqualified to give investment recommendations. Always do your research and consult with a licensed investment professional before investing. This communication is not to be used as the foundation for making investment decisions and is for entertainment purposes only. This communication should serve only as a starting point of your research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, or staff responsible for any damages, financial or otherwise, that may occur due to any action you may take based
on the information contained within our website/media webpage. We do not advise any reader to take any specific action. Losses can be fatal if the company experiences any problems with liquidity or wide spreads. Our website/media webpage is for entertainment purposes only. Gains mentioned in our website/media webpage may be based on end-of-day or intraday data. Do not make an investment decision based on
This publication, its owners, and affiliates may hold positions in the securities mentioned in our alerts; these may sell at any time without notice to our subscribers, which may hurt share prices. 154 Agency business model is to receive financial compensation to promote public companies. This includes, but is not limited to: conducting investor relations advertising, marketing, and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased, and therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third-party, profiled company or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely to expand our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors We do not guarantee the timeliness, accuracy, or completeness of the information on our website/media webpage. The information in our website/media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, 154 Agency often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double- checked and verified before publication, but there is always the possibility of errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all our communications is incorrect until you verify the information. We encourage you to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.